Laboratory Testing Division

WuXi AppTec Names John Pirro as Senior Director

Posted by WuXi AppTec Industry Expert on Sep 26, 2018 9:34:54 AM

We are pleased to announce that John Pirro has joined our team as a Senior Director in WuXi AppTec Laboratory Testing Division’s Large Molecule Bioanalytical Services.


With more than 20 years of experience in large molecule assay development and analysis, John Pirro will lead the Large Molecule Bioanalysis program at WuXi AppTec Laboratory Testing Division's New Jersey site as well as support customers with relevant inquiries in support of their preclinical and clinical PK/TK/PD, ADA and vaccine studies. He will serve as a consultant for FDA inquires, and ensure scientific integrity and GLP compliance. He will also serve as a technical expert and assist the labs with study design, data interpretation, failure analysis and corrective actions.

John’s experience includes 12 years in pharmaceutical companies and 6 years in established CRO such as Charles River Laboratories, where he set up the first proteomic lab in Worchester, Massachusetts. He also worked as VP/COO of MDS Pharma Services in Montreal, Quebec, Canada, where he helped address data quality issues with the FDA. From there, John continued working with a number of companies developing large molecule assays and setting up labs for growth. He has published 24 papers in various peer-reviewed journals, focusing on topics such as novel plasma proteomic analysis – plasma depletion, fractionation and separation strategy using IgY antibodies.

John served 8 years in the US Naval reserve and has rich experience in CRO’s changing culture, succession planning, leadership and voice of the customer. He is an expert in designing and implementing new bioanalytical methods and standardized procedures. He holds 9 US patents and has been invited to speak at many trade publication interviews.

Please contact your account manager or email John Pirro to learn more about how WuXi AppTec’s Large Molecule Bioanalysis Services can support your large molecule preclinical studies and first-in-human trial.